The congenital protein C deficiency treatment ‘Ceprotin Inj’ was recognized as adequate for reimbursement by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC).

As a result, its final reimbursement will be determined through pricing negotiations with the National Health Insurance Service.

The committee decided so at its 6th 2024 meeting that was held on the 13th.

Takeda Pharmaceutical’s Ceprotin Inj (human protein C) is the first human protein C concentrate drug to treat congenital protein C deficiency. The drug, which was approved in Korea in 2022, treats venous thrombosis and fulminant purpura in patients with congenital